Article 289: Expanding the Boundaries of CRO Partnerships

• During the past several years, contract research organizations (CROs) including PPD, Quintiles and AaiPharma have expanded their abilities to perform most drug development company functions – from discovery of new molecules to selling approved drugs. Client companies are largely comfortable and eager to leverage these broadening capabilities.

Article 290: Revisiting the Online Matchmaker Market

• Internet-based companies that match patients to trials are tempering their promises and changing their business models in order to differentiate themselves in a skeptical market where adoption has been limited.

Article 291: CentreStage Europe: A Tenuous SMO Market in Europe

• European site management organizations are continuing to struggle to gain recognition as valuable assets in the clinical trial process. The SMO market in Europe remains poorly understood and ill-defined.

Article 292: Eye On: HIV/AIDS

• CenterWatch has identified a pipeline of 52 drugs in development for HIV/AIDS, including immune modulators, fusion inhibitors, vaccines and others.